U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H24ClNO.C20H14O4
Molecular Weight 648.186
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOPERASTINE FENDIZOATE

SMILES

ClC1=CC=C(C=C1)C(OCCN2CCCCC2)C3=CC=CC=C3.OC(=O)C4=C(C=CC=C4)C(=O)C5=CC=C(O)C(=C5)C6=CC=CC=C6

InChI

InChIKey=PXZFKAKWSHBDCP-UHFFFAOYSA-N
InChI=1S/C20H24ClNO.C20H14O4/c21-19-11-9-18(10-12-19)20(17-7-3-1-4-8-17)23-16-15-22-13-5-2-6-14-22;21-18-11-10-14(12-17(18)13-6-2-1-3-7-13)19(22)15-8-4-5-9-16(15)20(23)24/h1,3-4,7-12,20H,2,5-6,13-16H2;1-12,21H,(H,23,24)

HIDE SMILES / InChI
Cloperastine (INN) or cloperastin is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981. The precise mechanism of action of cloperastine is not fully clear, but several different biological activities have been identified for the drug, of which include: ligand of the gamma1 receptor (Ki = 20 nM) (likely an agonist), GIRK channel blocker (described as "potent"), antihistamine (Ki = 3.8 nM for the H1 receptor), and anticholinergic. Cloperastine possesses dual activity. It also acts as a mild bronchorelaxant and has antihistaminic activity, without acting on the central nervous system or the respiratory center.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Ameliorating effects of cloperastine on dysfunction of the urinary bladder caused by cerebral infarction in conscious rats.
2009 Nov
[Novel antidepressant-like action of drugs possessing GIRK channel blocking action in rats].
2010 May
Cloperastine-based cough syrup and acute dystonic reactions.
2012 Mar
Cloperastine rescues impairment of passive avoidance response in mice prenatally exposed to diethylstilbestrol.
2014 Feb
Patents

Patents

Sample Use Guides

10–20 mg three times daily for adults
Route of Administration: Oral
In Vitro Use Guide
Cloperastine inhibited the hERG K⁺ channels, expressed in HEK293 cells, in a concentration-dependent manner with an IC₅₀ value of 0.027 μM
Name Type Language
CLOPERASTINE FENDIZOATE
JAN   MART.   WHO-DD  
Common Name English
CLOPERASTINE FENDIZOATE [MART.]
Common Name English
BENZOIC ACID, 2-((6-HYDROXY(1,1'-BIPHENYL)-3-YL)CARBONYL)-, COMPD. WITH 1-(2-((4-CHLOROPHENYL)PHENYLMETHOXY)ETHYL)PIPERIDINE (1:1)
Common Name English
CLOPERASTINE FENDIZOATE [JAN]
Common Name English
Cloperastine fendizoate [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
Code System Code Type Description
ECHA (EC/EINECS)
286-126-9
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
PRIMARY
SMS_ID
100000091940
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
PRIMARY
EVMPD
SUB01366MIG
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
PRIMARY
PUBCHEM
163446
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
PRIMARY
EPA CompTox
DTXSID00100564
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
PRIMARY
CAS
85187-37-7
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
PRIMARY
FDA UNII
2M105305SU
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
PRIMARY
ChEMBL
CHEMBL415087
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
PRIMARY
NCI_THESAURUS
C95234
Created by admin on Fri Dec 15 17:41:15 GMT 2023 , Edited by admin on Fri Dec 15 17:41:15 GMT 2023
PRIMARY